Advertisement

Tumor Biology

, Volume 35, Issue 3, pp 2313–2318 | Cite as

Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer

  • Dan Su
  • Shun-Chang Jiao
  • Li-Jie Wang
  • Wei-Wei Shi
  • Yan-Yan Long
  • Juan Li
  • Li Bai
Research Article

Abstract

Advanced pancreatic cancer patients have poor prognosis and scarcely respond to conventional therapies. Clinical trials support the use of molecular-targeted therapy against epidermal growth factor receptor (EGFR) signaling. The objective of the current study was to evaluate the contribution of a monoclonal antibody against EGFR, nimotuzumab, to standard gemcitabine therapy. Patients with unresectable locally advanced or metastatic pancreatic adenocarcinoma were assigned to receive gemcitabine plus nimotuzumab. The primary end point was overall survival, whereas the secondary end points included progression-free survival, objective response, and adverse side effects. A total of 18 eligible patients were accrued between December 2007 and July 2010. The disease control rate, calculated as the sum of complete response, partial response, and stable disease, was 55.6 %. The median overall survival time was 9.29 months (95 % CI, 5.499 to 13.072). The median progression-free survival was 3.71 months (95 % CI, 2.526 to 4.902), and the 1-year survival rate was 38.9 %. Of all the patients, 88.8 % had at least one adverse side effect; however, no grade 4 adverse side effect was reported. Nimotuzumab as a high-purity humanized monoclonal antibody with favorable safety profile, its value in the treatment of pancreatic cancer along with gemcitabine, particularly in the comprehensive treatment of advanced pancreatic cancer, is appealing for further prospective randomized large-scale clinical trials.

Keywords

Pancreatic carcinoma EGFR inhibitor Nimotuzumab Gemcitabine Monoclonal antibody 

Notes

Conflicts of interest

None

References

  1. 1.
    GLOBOCAN. Estimated cancer Incidence, Mortality, Prevalence and Disability-adjusted life years (DALYs) Worldwide in 2008. 2008; http://globocan.iarc.fr/. Accessed 15 March 2013.
  2. 2.
    Jemal A, Siegel R, Ward E, et al. Cancer statistics 2007. CA Cancer J Clin. 2007;57:43–66.PubMedCrossRefGoogle Scholar
  3. 3.
    Li D, Xie K, Wolff R, et al. Pancreatic cancer. Lancet. 2004;363:1049–57.PubMedCrossRefGoogle Scholar
  4. 4.
    O'Sullivan A, Kocher HM. Pancreatic cancer. Br Med J Clin Evid. 2007;11:409–37.Google Scholar
  5. 5.
    Wray CJ, Ahmad SA, Matthews JB, et al. Surgery for pancreatic cancer: recent controversies and current practice. Gastroenterology. 2005;128:1626–41.PubMedCrossRefGoogle Scholar
  6. 6.
    Rosewicz S, Wiedenmann B. Pancreatic carcinoma. Lancet. 1997;349:485–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.PubMedGoogle Scholar
  8. 8.
    Hu J, Zhao G, Wang HX, et al. A meta-analysis of gemcitabine containing chemotherapy for locally advanced and metastatic pancreatic adenocarcinoma. J Hematol Oncol. 2011;4:11.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Strimpakos AS, Syrigos KN, Saif MW. Novel agents in early phase clinical studies on refractory pancreatic cancer. JOP. 2012;13:166–8.PubMedGoogle Scholar
  10. 10.
    Lowery MA, O'Reilly EM. Genomics and pharmacogenomics of pancreatic adenocarcinoma. Pharmacogenomics J. 2012;12:1–9.PubMedCrossRefGoogle Scholar
  11. 11.
    Campen CJ, Dragovich T, Baker AF. Management strategies in pancreatic cancer. Am J Health Syst Pharm. 2011;68:573–84.PubMedCrossRefGoogle Scholar
  12. 12.
    Yip D, Karapetis C, Strickland A, et al. WITHDRAWN: Chemotherapy and radiotherapy for inoperable advanced pancreatic cancer. Cochrane Database Syst Rev. 2009;4:CD002093.Google Scholar
  13. 13.
    Kelley RK, Ko AH. Erlotinib in the treatment of advanced pancreatic cancer. Biologics: Targets & Therapy. 2008;2:83–95.Google Scholar
  14. 14.
    Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol. 2006;33:369–85.PubMedCrossRefGoogle Scholar
  15. 15.
    Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183–232.PubMedCrossRefGoogle Scholar
  16. 16.
    Troiani T, Martinelli E, Capasso A, et al. Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets. 2012;13:802–10.PubMedCrossRefGoogle Scholar
  17. 17.
    Heinemann V, Haas M, Boeck S. Systemic treatment of advanced pancreatic cancer. Cancer Treat Rev. 2012;38:843–53.PubMedCrossRefGoogle Scholar
  18. 18.
    Naraev BG, Strosberg JR, Halfdanarson TR. Current status and perspectives of targeted therapy in well-differentiated neuroendocrine tumors. Oncology. 2012;83:117–27.PubMedCrossRefGoogle Scholar
  19. 19.
    Talavera A, Friemann R, Gomez-Puerta S, et al. Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation. Cancer Res. 2009;69:5851–9.PubMedCrossRefGoogle Scholar
  20. 20.
    Boland WK, Bebb G. Nimotuzumab: a novel anti-EGFR mono-clonal antibody that retains anti-EGFR activity while minimizing skin toxicity. Expert Opin Biol Ther. 2009;9:1199–206.PubMedCrossRefGoogle Scholar
  21. 21.
    Strumberg D, Schultheis B, Scheulen ME, et al. Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Invest New Drugs. 2012;30:1138–43.PubMedCrossRefGoogle Scholar
  22. 22.
    Strumberg D, Schultheis B, Scheulen ME, et al. Safety, efficacy and pharmacokinetics of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer. Int J Clin Pharmacol Ther. 2010;48:473–5.PubMedCrossRefGoogle Scholar
  23. 23.
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRefGoogle Scholar
  24. 24.
    Eltawil KM, Renfrew PD, Molinari M. Meta-analysis of phase III randomized trials of molecular targeted therapies for advanced pancreatic cancer. HPB (Oxford). 2012;14:260–8.CrossRefGoogle Scholar
  25. 25.
    Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. J Clin Oncol. 2010;28:3605–10.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Rivera F, Vega-Villegas ME, Lopez-Brea MF, et al. Current situation of Panitumumab, Matuzumab, Nimotuzumab and Zalutumumab. Acta Oncol. 2008;47:9–19.PubMedCrossRefGoogle Scholar
  27. 27.
    Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer. A phase III trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC-CTG). J Clin Oncol. 2005;23:16s.Google Scholar
  28. 28.
    Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared to gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.PubMedCrossRefGoogle Scholar
  29. 29.
    Faloppi L, Andrikou K, Cascinu S. Cetuximab: still an option in the treatment of pancreatic cancer? Expert Opin Biol Ther. 2013;13:791–801.PubMedCrossRefGoogle Scholar
  30. 30.
    Fensterer H, Schade-Brittinger C, Müller HH, et al. Multicenter phase II trial to investigate safety and efficacy of gemcitabine combined with cetuximab as adjuvant therapy in pancreatic cancer (ATIP). Ann Oncol. 2013;24:2576–81.PubMedCrossRefGoogle Scholar
  31. 31.
    Cheng YJ, Bai CM, Zhang ZJ. Efficacy of gemcitabine combined with erlotinib in patients with advanced pancreatic cancer. Acta Acad Med Sin. 2010;32:421–3.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  • Dan Su
    • 1
  • Shun-Chang Jiao
    • 1
  • Li-Jie Wang
    • 1
  • Wei-Wei Shi
    • 1
  • Yan-Yan Long
    • 1
  • Juan Li
    • 1
  • Li Bai
    • 1
  1. 1.Department of Oncology MedicineChinese PLA General HospitalBeijingChina

Personalised recommendations